title: Bias in the reporting of harms in clinical trials of second-generation antidepressants: The tip of the iceberg?
abstract: Serious adverse events are poorly reported in clinical trials of second-generation antidepressants. Moreover some key opinion leaders (eg. in France) deliberately failed to warn against them. The gross distortions of antidepressants' benefit:harm ratio in adolescents showed evidence that open science (ie access to de-identified individual patient data for re-analyses) is a mandatory prerequisite for a trustworthy science.
authors.affiliation: Alcohol Treatment Unit, Amiens University Hospital, 80000 Amiens, France. Electronic address: braillon.alain@gmail.com.
authors.forename: Alain
authors.initials: A
authors.lastname: Braillon
authors.affiliation: Meta-Research Innovation Center (METRICS), Stanford University, 94304 Palo Alto, CA, USA.
authors.forename: Florian
authors.initials: F
authors.lastname: Naudet
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D003863:Depression / Q000188:drug therapy*; D006801:Humans
chemical_list: D000928:Antidepressive Agents
keywords: Antidepressants; Clinical trials; Industry; Research integrity; Serious adverse events